<DOC>
	<DOCNO>NCT01617954</DOCNO>
	<brief_summary>This prospective study assess impact MammaPrint chemotherapy + endocrine versus endocrine alone treatment decision patient Oncotype Intermediate Score .</brief_summary>
	<brief_title>PRospective Study Of MammaPrint Patients With Intermediate Recurrence Score</brief_title>
	<detailed_description>The frequency chemotherapy + endocrine versus endocrine alone decision Oncotype DX intermediate score patient calculate receive MammaPrint result .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women histologically proven invasive stage III , node negative , hormone receptor positive , Her2 negative breast cancer , receive Oncotype DX intermediate score ( 1830 ) ≥ 18 year age time consent Written inform consent Insufficient tissue remain Mammaprint FFPE Tumor sample ship Agendia ≤ 30 % tumor cell fail QA QC criterion Women start complete adjuvant chemotherapy neoadjuvant chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>